To further validate the role of the β1-integrin-FAK-YAP1/TAZ signaling axis in cancer cell survival and growth on ECM, we treated cancer cells with pharmacological inhibitors PF-228 or verteporfin to target against FAK or YAP1 respectively. This evidence concerns the gene YAP1 and cancer.